CM-326

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameCM-326
Drug Alias NameCM-326
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, AtopicNasal Polyps +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesKeymed Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCspc Baike (Shandong) Biopharmaceutical Co LtdKeymed Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, AtopicPulmonary Disease, Chronic Obstructive +[4] 
Inactive IndicationsNasal PolypsSinusitis

Other Information

ATC CodeN/A
Related LinksN/A